灵智系列实验室冻干机
Search documents
首台国产十万转超速离心机发布 海尔生物以技术领航构建生命科学新生态
Jin Rong Jie· 2025-11-08 00:10
Core Insights - The article emphasizes the importance of independent innovation and self-reliance in high-end scientific instruments, particularly in the context of China's "14th Five-Year Plan" which promotes technological self-sufficiency and the cultivation of emerging industries [1][3][11] - Haier Biomedical has achieved a significant breakthrough by launching a super-speed centrifuge that exceeds 100,000 RPM, marking a transition from reliance on imports to self-sufficiency in high-end life science instruments [1][5][9] Industry Overview - The demand for ultra-speed centrifuges is increasing due to advancements in cell therapy, vaccine development, and pharmaceutical processes, necessitating higher efficiency and precision in laboratory operations [3][5] - Despite improvements in domestic high-speed centrifuges, the high-end market remains dominated by international brands, with domestic products holding only 38% of the market share as of 2025 [3][5] Company Developments - Haier Biomedical's new centrifuge not only meets international standards in terms of stability and data security but also offers customizable data management features, enhancing safety and compliance for laboratory personnel [5][6] - The company is transitioning from being a mere equipment supplier to a service provider, focusing on creating intelligent laboratory solutions that cater to the specific needs of researchers [6][10] Product Innovations - In addition to the super-speed centrifuge, Haier Biomedical showcased several advanced products at the China International Import Expo, including a rapid freezing instrument and an automated cell expansion system, which are designed to meet the growing demands of life science research [7][8] - The rapid freezing instrument can achieve cooling rates of 10,000°C/s, preserving sample integrity for high-resolution structural analysis [7] Market Potential - The global life science tools market is projected to grow from approximately $161.57 billion in 2023 to over $330.69 billion by 2030, with a compound annual growth rate of 10.8% [11] - As the global pharmaceutical R&D spending increases, the demand for high-quality laboratory instruments and tools is expected to rise significantly, presenting opportunities for companies like Haier Biomedical to expand their market presence [10][11]